Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q2 FY2026 depreciation & amortization of $30.42K rose 4.5% year over year, ahead of the +3.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.
Context
- Depreciation & amortization amounted to 8.3% of revenue in FY2025.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of +3.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 117.05K USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- -18.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 117.05K | +2.8% |
| FY2024 | 2024-09-30 | 113.86K | +157.7% |
| FY2023 | 2023-09-30 | 44.19K | -78.4% |
| FY2022 | 2022-09-30 | 204.69K | -21.9% |
| FY2021 | 2021-09-30 | 262.14K | — |
Depreciation & Amortization vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 depreciation & amortization of $119.64K is the 8th largest of the 9 companies compared; the peer median is $2.06M.
- Its year-over-year change of +3.7% is the 7th highest of 9, against a peer median of +66.5%.
- Depreciation & amortization amounts to 35.9% of revenue for OTLK, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $363.33M | +106428.1% | +7569.0% | — |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $2.9M | +21.7% | -19.1% | 8.9% | |
| LTM Mar 2026 | $1.23M | +12.3% | +6.9% | 86.8% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| Peer median (excluding OTLK) | $2.06M | +66.5% | +10.4% | 15.3% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.